Hikal Limited has rescheduled its earnings conference call to discuss its financial and operational performance for the quarter and fiscal year ended March 31, 2026. The meeting, originally set for 4:30 PM IST, will now be held on May 27, 2026, at 5:30 PM IST. This adjustment provides investors and analysts a revised opportunity to hear directly from the company's leadership regarding the results for Q4 and FY26.

The disclosure was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation serves as a formal update to the earlier communication dated May 20, 2026, ensuring all stakeholders are aligned with the new timing.

Key members of the management team will lead the discussion. The participants include Mr. Sameer Hiremath, Vice Chairman and Managing Director; Mr. Kuldeep Jain, Chief Financial Officer; Mr. Anish Swadi, Senior President, Business Transformation and Animal Health; and Mr. Manoj Mehrotra, President, Pharmaceuticals Business.

The conference call offers universal access for domestic and international investors. Participants can join via specific dial-in numbers provided for various regions, including Hong Kong, Singapore, the UK, and the USA. Strategic Growth Advisors Pvt. Ltd. is handling the RSVP coordination for the event.

HIKAL has indicated that its new specialty chemicals and personal care products are expected to begin making significant contributions to its business starting FY27. The company's forward momentum is underpinned by a strengthened CDMO pipeline, which is seen as a key driver of stronger growth in the near term.

New Business Segments Poised for Impact

HIKAL's management has highlighted two emerging areas—specialty chemicals and personal care products—as pivotal to the company's growth trajectory from FY27 onwards. These segments represent a strategic expansion of the company's existing portfolio, aimed at diversifying revenue streams and capturing opportunities in high-value markets.

CDMO Pipeline Expansion Supports Outlook

Alongside the new product segments, HIKAL's expanded CDMO pipeline is expected to play a central role in accelerating growth. The CDMO business, which involves developing and manufacturing products on behalf of other companies, adds depth to HIKAL's service offerings and strengthens its position in the pharmaceutical and chemicals value chain.

• New specialty chemicals segment anticipated to contribute meaningfully from FY27
• Personal care products identified as an additional growth avenue
• Expanded CDMO pipeline expected to bolster overall business performance
• Strategic diversification aimed at enhancing long-term revenue visibility

HIKAL's dual focus on expanding its product portfolio and scaling its CDMO capabilities reflects a deliberate strategy to broaden its business base. The anticipated contributions from FY27 onwards signal the company's confidence in the commercial readiness of these new initiatives.